Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
197 Results for "
Cancer therapy
" in MedChemExpress (MCE) Product Catalog:
Products (197)
197 Results for "Cancer therapy" in MCE Product Catalog:
Cat. No.: HY-141520G
CAS No.: 2603528-97-6
Cat. No.: HY-N16394
CAS No.: 103614-68-2
Category:
Target:
Cat. No.: HY-W127809
CAS No.: 550-52-7
Cat. No.: HY-164523
CAS No.: 1093793-11-3
Target:
Research Areas:
PV1162 is a selective Chk2 inhibitor with an IC50 of 0.29 nM. PV1162 inhibits ATP binding to Chk2 by targeting the gatekeeper-dependent hydrophobic pocket, which is specific to Chk2 and located behind the ATP-binding site (adenine-binding region), thereby inhibiting the phosphorylation activity of Chk2. PV1162 holds potential application value in the field of cancer therapy .
Cat. No.: HY-175633
Research Areas:
ML210-ansaFc (Compound III-13) is a covalent GPX4 inhibitor with a -ferrocenophane group (IC50 of 3.4 μM). ML210-ansaFc potently induces ferroptosis by increasing the level of ROSand promoting lipid peroxidation (LPO) in cancers cells. ML210-ansaFc has an anticancer activity and suppresses tumor growth in tumor 3D spheroids. ML210-ansaFc can be used for cancer therapy resistance research .
Cat. No.: HY-110368
CAS No.: 1883548-83-1
BS-181 dihydrochloride is a potent and selective CDK7 inhibitor (IC50=21 nM) than Seliciclib (HY-30237). BS-181 is also against CDK2, CDK5 and CDK9 with IC50 values of 880 nM, 3000 nM and 4200 nM, respectively (fails to block CDK1, 4 and 6). BS-181 dihydrochloride inhibits a panel of cancer cells growth (IC50=11.5 μM-37.3 μM) and induces cell apoptosis. BS-181 dihydrochloride has the potential for the research of cancer therapy .
Cat. No.: HY-15150G
CAS No.: 1037624-75-1
Synonyms: R428 (GMP); BGB324 (GMP)
Cat. No.: HY-20457G
CAS No.: 1268163-15-0
Cat. No.: HY-D1673
CAS No.: 623903-26-4
Target:
Research Areas:
Tetrabromorhodamine 123 (TBR) bromide is a photosensitizer. Tetrabromorhodamine 123 bromide can be used for the research of photo dynamic therapy (PDT) and cancer .
Cat. No.: HY-128937
CAS No.: 1602487-15-9
Target:
Research Areas:
EC1454 is a peptide compound with anticancer activity that targets folate receptor-expressing cancers. EC1454 is a folate-tubulysin conjugate that can be used to prepare drug delivery conjugates for targeted therapy .
Cat. No.: HY-P991689
CAS No.: 3024821-77-7
Cat. No.: HY-14919
CAS No.: 284019-34-7
Synonyms: MN-029 free base
Target:
Research Areas:
Denibulin, a novel vascular-disrupting agent, inhibits microtubule assembly reversibly, disrupting tumor vascular endothelial cell cytoskeletons. Denibulin demonstrated tolerability and potential anti-vascular effects, warranting further investigation in cancer therapy .
Cat. No.: HY-N15349
CAS No.: 1558013-79-8
Category:
Target:
Cat. No.: HY-175214
Research Areas:
Antitumor photosensitizer-9 is a near-infrared Photosensitizer (PS) with a high singlet oxygen production rate (relative rate = 1.79). Antitumor photosensitizer-9 exhibits strong phototoxicity against various cancer cells and induces ROS generation under light irradiation. Antitumor photosensitizer-9 inhibits tumor growth in vivo and exhibits excellent anticancer photodynamic therapy (PDT) efficacy at low drug and light doses. Antitumor photosensitizer-9 can be used in photodynamic therapy research .
Cat. No.: HY-151940
CAS No.: 2670367-74-3
Target:
Research Areas:
Mal-Pc is a versatile molecular photosensitizer designed based phthalocyanine and maleimides. Mal-Pc can react with GSH to deplete GSH and reduce aggregation, thereby improving ROS (Reactive Oxygen Species)-mediated effect of photodynamic therapy (PDT) in cancer cells .
Cat. No.: HY-118974
CAS No.: 225925-12-2
Target:
Research Areas:
PD-151307 is an N-type calcium channel antagonist with significant inhibitory effects in IMR-32 human neuroblastoma cells, exhibiting an IC50 of 0.32 µM. PD-151307 can be used in research related to cancer therapy, anticonvulsants, and neuropathic pain .
Cat. No.: HY-162575
CAS No.: 128519-30-2
Anticancer agent 231 (Compound P5) is a tyrosine protein kinase inhibitor with a IC50 value of 3.95 μM. Anticancer agent 231 inhibits the cell viability, cell proliferation, cell migration and cancer dryness of triple negative breast cancer (TNBC) cells by targeting EGFR-ERK 1/2 signaling pathway, and is expected to play an important role in the field of TNBC disease therapy .
Cat. No.: HY-P10711
Cat. No.: HY-169517
CAS No.: 871317-00-9
Target:
Research Areas:
Protein kinase inhibitor 10 is a protein kinase inhibitor with IC50 values of 28.9, 13.6, and 2.41 μM for TAM receptor, FAK, and KIT, respectively. Protein kinase inhibitor 10 can inhibit abnormal and excessive cell proliferation, showing promise for research in cancer therapy .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
